-
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
27 May 2024 11:17 GMT
… here.
References
1.
National Cancer Institute. SEER Cancer Statistics Factsheets: Lung … 47;cancer-types/lung-cancer-non-small-cell/ … TROP2 in non‐small lung cancers and its correlation with … cancer/types/lung-cancer/treating-non-small- …
-
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
27 May 2024 06:20 GMT
Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial …
-
Northwestern develops successful double-lung transplant technique for cancer patients
28 May 2024 16:38 GMT
Bharat
TERESA CRAWFORD
For decades, double lung transplants were not considered a viable option for treating lung cancer.
“It had been done, but it had always failed,” said Ankit Bharat, chief of thoracic surgery at Northwestern Medicine. “When you took …
-
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
28 May 2024 13:19 GMT
This week on Pipeline Moves, we kick off by looking at a Phase III trial of GlycoMimetics’ uproleselan sodium which failed to meet its primary endpoint.
Meanwhile, an Investigator-led trial of AztraZeneca’s Lynparza was suspended and Bristol Myers Squibb …
-
These Human-Made Items Carry Carcinogens that Cause Cancer
27 May 2024 17:52 GMT
Sir Percival Pott, a London physician in 1775, felt sorry for chimney sweeps. They were child laborers who Pott thought were treated cruelly. They were poorly fed, barely clothed, and forced to ascend into sooty chimneys. Too often, Pott saw they were “ …
-
New UCSF study to find out what drives cancer in Asian Americans
25 May 2024 00:10 GMT
Scarlett Gomez, PHd, MPH, left, and Debby Oh examine a map of the California Bay Area that displays cancer data. Photo by Noah Berger.
National Cancer Institute awards $12.45 million to lead the first long-term cancer study of diverse U.S. Asian ethnic …
-
Bringing the Human Factor to the “Last Mile” of AI-Assisted Clinical Decisions
24 May 2024 22:07 GMT
Clinical trials can demonstrate a drug’s efficacy and safety. Biomarker tests can match the right drug with the right patient. FDA can give its approval, and the National Comprehensive Cancer Network (NCCN) can add a new therapy to its guidelines.
After …
-
5 FDA Solid Tumor Approvals from Spring 2024
24 May 2024 21:49 GMT
During the spring of 2024, the Food and Drug Administration (FDA) approved several new treatments for solid tumors. From new approvals for rare cancer types, such as small cell lung cancer (SCLC) and pediatric low-grade glioma, here’s a list of five new …
-
ARROS-1 Trial of Zidesamtinib Aims to Address Current TKI Limitations in ROS1+ NSCLC
24 May 2024 18:02 GMT
… EORTC-NCI-AACR (European Organisation for Research and Treatment of Cancer, National Cancer Institute … -ros1-positive-non-small-cell-lung-cancer
AnHeart Therapeutics receives FDA breakthrough …
-
Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab
24 May 2024 14:04 GMT
Introduction
According to Global Cancer Statistics 2020,1 breast cancer has surpassed lung cancer, becoming the most prevalent cancer among women worldwide. It is known to us that compared with other pathologic subtypes of breast cancer, overexpression of …